Table 4.

Predictors of follow-up pain interference (ref: no pain/decreased pain interference) n=2303

		Demographics	Demographics and Clinical
		New/Continued/Highe r Pain interference †	New/Continued/Higher Pain interference †
Demographics		OR (95% CI)	OR (95% CI)
Race (ref*=White)
	African American	1.09 (0.83-1.43)	1.15 (0.85-1.55)
	Hispanic	0.92 (0.63-1.33)	0.91 (0.61-1.35)
	Asian	0.72 (0.43-1.22)	0.86 (0.50-1.48)
Age (ref=<54 years)
	55 to 64	0.90 (0.69-1.18)	0.82 (0.61-1.09)
	65 to 74	0.47 (0.35-0.63)	0.46 (0.33-0.63)
	≥75	0.61 (0.45-0.82)	0.66 (0.47-0.93)
Sex (ref=male)
	Female	1.23 (1.01-1.50)	1.33 (1.07-1.65)
Income (ref=≥$60,000)
	<$20,000	2.06 (1.51-2.82)	1.57 (1.22-2.20)
	$20,000 to <$40,000	1.58 (1.17-2.12)	1.30 (0.97-1.78)
	$40,000 to <$60,000	0.99 (0.71-1.39)	0.93 (0.66-1.31)
Education (ref= College degree or higher)
	Less than high school	1.19 (0.84-1.68)	1.23 (0.85-1.78)
	High school graduate/GED	1.41 (1.06-1.86)	1.32 (0.98-1.78)
	Some college/ vocational school	1.05 (0.79-1.39)	1.00 (0.75-1.34)
Clinical characteristics
Time since diagnosis (days)			0.99 (0.99-1.00)
Stage at diagnosis (ref=Stage I)
	Stage II		0.93 (0.69-1.26)
	Stage III		0.92 (0.65-1.32)
	Stage IV		1.42 (0.94-2.17)
Treatment† (ref=neither)
	Chemotherapy or radiation only		1.00 (0.73-1.38)
	Chemotherapy and Radiation		1.78 (1.24-2.55)
Stoma (ref=no)
	Yes		1.21 (0.87-1.69)
Diabetes (ref=no)
	Yes		1.52 (1.17-1.98)
Kidney disease (ref=no)
	Yes		1.21 (0.86-1.69)
Crohn’s disease (ref=no)
	Yes		1.33 (0.73-2.42)
Pulmonary disease (ref=no)
	Yes		2.01 (1.49-2.71)
Heart failure (ref=no)
	Yes		2.23 (1.38-3.60)
Heart attack (ref=no)
	Yes		1.27 (0.87-1.86)
Stroke (ref=no)
	Yes		1.45 (0.99-2.12)
Depression (ref=no)
	Yes		1.55 (1.21-2.00)
Goodness-of-fit (Hosmer-Lemeshow)
X2 (df) p-value		9.87 (8) p=0.275	4.06 (8) p=0.851
C-statistic		0.62	0.69

^*Ref = Reference category;

^†Treatments that had been received by the time of the follow-up survey.